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Abstract 
Background: Pegylated interferon and ribavirin are currently one of the accepted treatment for chronic 
Hepatitis C. Dermatologic complications of interferon have been reported, but to date a few cases of bacterial 
cellulitis; a rare and severe complication, have been published. Cellulitis is a common infectious process 
affecting the skin and subcutaneous tissues which results in significant morbidity and holds considerable 
healthcare costs. 
Cases Report: Herein, we report a case of chronic hepatitis C genotype 1a who was on medication since 8 
weeks prior to developing leg cellulitis, an uncommon pegylated interferon injection site. Considering no other 
possible risk factors were found to be in favor of bacterial cellulitis, our case is unique in its kind. Some reports 
reveal necrotizing vasculitis as basis for cutaneous lesions, which could be due to the high concentrations of 
drug at the injection site, a toxic effect of the diluents, or an immunological reaction. 
Conclusion: According to the latter mechanism patients could develop bacterial cellulitis in their different 
organs. Conclusively, we propose the hypothesis of a possible association between cellulitis to occur at any site 
as the complication of pegylated interferon Alfa 2b and would highlight the role of a careful skin examination 
that could be an asset in preventing local skin infections. 
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One of the current treatments for chronic hepatitis C 
is the combination of pegylated interferon and 
ribavirin. Previously, interferon was the only 
treatment, but the addition of a polyethylene-glycol 
side chain (pegylation) to the interferon gives it a 
much longer bioavailability, allowing for weekly 
injections rather than three injections per week1. 
When combined with pegylated interferon, ribavirin 
improves biochemical and virological response rates 
for most populations to 42 to 46 percent for patients 
with genotype 11,2 and 76 to 82 percent for patients 
with genotypes 2 and 32.  
Pegylated interferon can cause wide range of 
complications such as neuropsychiatric emergencies, 
autoimmune reactions, ischemia, and infections 
including soft tissue problems3. Dermatologic 
complications of interferon Alfa have been reported, 
such as inflammatory reactions at the injection site, 
non-specific dermatitis and pruritis4-7. Although cases 
of cutaneous ulceration have been reported with 
pegylated interferon Alfa prescribed for melanoma8, 
few cases of bacterial cellulitis, a rare and severe 
complication of pegylated interferon Alfa, have been 
described as a consequence of subcutaneous 
NBM 41   Novelty in Biomedicine 2016, 1, 41-4 
Sali et al.                                                                            Peg-Interferon Alfa 2-b Related Cellulitis in a 40 Years Man 
injections9. Hereby we report a case whose cellulitis 
was presented on his leg, not a common pegylated 
interferon injection site, considering no other 
possible risk factor found to be in favor of 
developing bacterial cellulitis. 
Case Report 
A 40-year-old man, a shopkeeper, born and current 
resident of Tehran, Iran, presented to Labbafi-nejad 
Hospital, affiliated for Shahid Beheshti Medical 
University (SBMU), with an acute onset of 
edematous left lower extremity. He had suffered 
from leg tenderness and warmth since a week prior to 
admission, which gradually had got worse with no 
obvious abcess. He had some pruritic and painful 
lesions on the lateral side of his leg, and couldn’t 
tolerate weight-bearing on his affected leg.    
The patient had hepatitis C genotype 1a, which was 
due to his previous intravenous drug abuse, since 9 
months ago and was under treatment with Pegylated 
interferon Alfa 2b pegintron:150µgr subcutaneously 
and ribavirin 600mg twice daily since 8 weeks ago. 
Furthermore, he denoted having car accident and a 
surgery on his affected leg 4 years ago, but did not 
mention any recent trauma to the affected leg. He 
didn’t have any other significant past medical or 
familial history. He was neither diabetic nor Hepatitis 
B nor Human Immunodeficiency Virus (HIV) 
infected. He denied a history of insect bites, ingestion 
of medications, or other inter-current illness. The 
patient’s complete immunizations had been received 
earlier. His habits consisted of occasional opioid 
consumption and smoking 20 pack-years.   
During last 8 weeks, he reported having fevers or 
chills after injection of pegintron. Physical 
examination revealed an area of erythema, edema 
and warmth, sized 95mm x 80mm, with exudates. 
There was obvious tenderness on the site. Erythema 
encompassed the lateral side of his left leg. No 
fluctuations were detected. On initial exam, he was 
normo-tensive at 125/80 mmHg, heart rate at 72 
beats/min, saturating 98% O2, and with a body 
temperature of 38.6°C. Arterial blood gasses 
demonstrated respiratory alkalosis. 
His laboratory studies were significant for a normal 
white blood cell count of 4,800 cells per cu mm, 
without peripheral neutrophilia (54%), maybe due to 
interferon he had relative leukopenia. The blood 
platelets count (126×103/μL) was low, erythrocyte 
sedimentation rate (ESR 31 mm/hr) was elevated and 
the C-reactive protein was 32mg/l. In addition, His 
blood and urine cultures had no growth. His leg wound 
cultures grew Gram Positive Cocci, staphylococcus 
aurous. Ultrasound scanning performed on the day 
following admission reported soft tissue edema and 
without collection, we planned to perform skin biopsy 
of affected skin but patient did not permit us. 
Subsequently, the patient was admitted with presumed 
bacterial cellulitis and was treated with intravenously 
administered Vancomycin at 1 gram every 12 hours, 
and Clindamycin at 6oo mg every 8 hours, for broad 
base coverage. His wounds were managed as per 
application of daily washing and clean dressing. The 
patient’s cutaneous symptoms improved within 72 
hours. IV antibiotic treatment was continued over 5 
days, and was discharged on Ciprofloxacin, 500 mg 
twice daily and Clindamycin, 300mg thrice daily. The 
patient was successfully managed and he subsequently 
was followed up in the infectious disease clinic 1 week 
later without any signs of infection. 
Discussion 
In some regimen Pegylated interferon is an essential 
component of the treatment in chronic hepatitis C 
virus (HCV) infection2. It comes in a pen injection 
system or a prefilled syringe10. Self-administering a 
subcutaneous injection can end in many intimidating 
consequences to some patients3.  
Dermatologic complications of subcutaneous 
injections of interferon Alfa such as inflammatory 
reactions at the injection site, non-specific dermatitis 
and pruritis have been previously reported. A few 
cases of local cutaneous necrosis have also been 
described5,7. In randomized therapeutic trials of 
chronic hepatitis C comparing pegylated interferon 
Alfa 2a and interferon Alfa 2a for 48 weeks 2, 
cutaneous side effects were found to be more frequent 
in the former. Bacterial cellulitis is a rare and severe 
complication of pegylated interferon Alfa 9, which is a 
common infectious process affecting the skin and 
subcutaneous tissues. Along with other skin and soft 
tissue infections, it results in significant morbidity and 
holds considerable healthcare costs11. The incidence of 
lower-extremity cellulitis in Olmsted County 
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(Minnesota) was estimated at 199 per 100,000 
person-years12. A recent study in Netherlands 
provided an incidence of about 2/1000/year when all 
forms of ‘cellulitis/erysipelas’ of the leg were taken 
together13. The Dutch study provided additional 
information: only 7% of the cases resulted in 
hospitalization, but these accounted for 83% of the 
total treatment costs. Not surprisingly the rate of 
hospital admission for ‘cellulitis/erysipelas’ 
increased sharply after 60 years of age to reach 
1/1000/year in those aged above 7514. 
At the present time, evidence-based clinical 
guidelines for diagnosis of cellulitis are lacking. 
Cellulitis is a clinical diagnosis and a potential 
medical emergency. Clinicians are given the 
challenging task of diagnosing a disease based on 
limited epidemiologic data and poorly characterized 
presenting symptoms15,16. As in our case, the 
diagnosis was made on clinical manifestation and 
ultrasound findings in respect of ethical rules. 
Many side effects and drug interactions cannot be 
detected when drugs are approved. Yu et al17 studied 
617 treatment-naive Chronic Hepatitis C patients 
prescribed a 24-week protocol of peg-IFN/RBV, 
among which 29 (4.7%) patients terminated 
treatment early at <20 weeks. The reasons for early 
termination were flu-like symptoms/signs (n=9, 
31.0%), irritability (n=1, 3.4%), severe urticaria 
(n=1, 3.4%), insomnia (n=2, 6.9%), pulmonary 
tuberculosis (n=1, 3.4%/o), suicide idea (n=2, 6.9%), 
poor response (n=2, 6.9%), depression (n=2, 6.9%), 
unwilling to continue (n=1, 3.4%), mortality (n=1, 
3.4%), gastrointestinal upset (n=1, 3.4%), 
pancytopenia complicated with cellulitis (n=1, 3.4%), 
anaemia (n=3, 10.3%), overseas work (n=1, 3.4%) 
and an unknown cause (n=1, 3.4%). 
Reported by El-Serag et al.18 patients with HCV had 
a significantly higher prevalence of bacterial 
infection, including peritonitis, sepsis, endocarditis, 
cellulitis, and carbuncles in comparison with healthy 
controls.  
Sixty-two (79%) HCV genotype 1 patients in a study 
by Howell et al.19 completed 48 weeks of 
combination treatment with peginterferon Alfa-2a 
plus ribavirin. A case of cellulitis on day 493 (22 
weeks after treatment was completed) was judged to 
be unrelated to treatment. These serious infections 
were not associated with severe neutropenia or 
lymphocytopenia. 
In the U.S. multicenter pilot study of daily consensus 
interferon plus ribavirin for “difficult to treat” HCV 
genotype 1 patients, Ho et al. investigated 64 patients 
with HCV genotype 1 to determine the efficacy and 
safety of daily pegylated interferon Alfa and ribavirin 
(RBV) for initial treatment. Overall early 
discontinuation of treatment before 24 weeks occurred 
in 34% of patients (9 due to intolerance; 10 due to 
noncompliance; 1 due to chest pain; and 2 due to 
cellulitis)20. 
In a study by Suza et al21 among 119 HCV patients 
treated with Interfrone and Ribavirin, 22 patients 
developed bacterial infections during or immediately 
after stopping therapy, 2 of which was diagnosed as 
cellulitis. Only 1 patient required hospital admission: a 
72-year-old man with Child’s Class A cirrhosis 
developed cellulitis and edema of the lower 
extremities associated with high fever and prostration 
after 28 weeks of combination therapy. He required 
intravenous antibiotics, and both interferon and 
ribavirin were discontinued. He had not had significant 
neutropenia before therapy (1,670 cells /L) or while on 
therapy (mean neutrophil count was 1,118 cells/L) and 
recovered with treatment. 
In a study of cellulitis among people who take 
peginterferon (peginterferon Alfa-2a; ribavirin) based 
on 8 reports from FDA and user community22, 991 
people reported to have side effects when taking 
peginterferon. Among them, 8 people (0.81%) have 
Cellulitis. The time on peginterferon when people 
have cellulitis was mainly in 1 to 6 months and 2 to 5 
years, similarly in our case the time between 
beginning of peginterferon and cellulitis presentation, 
8 weeks, is in favor of causal association. 
Contradictly, most of patients taking peginterferon 
who have cellulitis were female (62.5% vs. 37.5%). 
Ages of people who have cellulitis were more than 40 
years with a peak on 50-59 years. Top conditions 
involved for these people were hepatitis C and 
thrombocytopenia respectively22.                                                                   
Fanny Lanternier et al. reported a case of 55 years 
diabetic man from Egypt with fever, chills and pain of 
the anterior left tight five months after beginning of 
Pegylated interferon–Alfa 2b and Ribavirin for chronic 
Hepatitis C genotype 4 and a positive skin culture for 
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non-group able Streptococcus sp.23 
Conclusion 
In our presented case cellulitis was not related to soft 
tissue infections of injection site, considering leg is 
not a common site for injection of pegylated 
interferon. Some pathologic reports reveal 
necrotizing vasculitis as basis for cutaneous lesions. 
It remains unclear whether vasculitis may be a result 
of the high concentrations of interferon at the 
injection site, of a toxic effect of the diluents, or of 
an immunological reaction9. According to the latter 
mechanism patients could develop bacterial cellulitis 
in their different organs. In conclusion, our case of 
leg bacterial cellulitis in a chronic HCV patient on 
pegylated interferon could propose the hypothesis of 
a possible association between cellulitis at any site as 
drug’s complication and pegylated interferon Alfa 
2b. Furthermore, the higher frequency of cutaneous 
side effects observed with pegylated interferon 
compared to classical interferon, a careful skin 
examination is recommended at all body sites in all 
patients, to prevent local skin infections such as 
cellulitis. 
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